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We have identiﬁed a new gene, gbp-5, with high homology to the guanylate binding proteins (GBP) belonging to the
GTPase superfamily including the ras gene. gbp-5 is transcribed at least into three splicing variants (gbp-5a, -5b,
and -5ta) leading to two different proteins (GBP-5a/b, GBP-5ta). GBP-5ta is C-terminally truncated by 97aa and has
therefore lost its isoprenylation site. Although RT-PCR results indicated expression of GBP-5 members in selected
normal tissues, western blotting using two newly generated antibodies revealed that expression of both proteins is
restricted to peripheral blood monocytes with GBP-5ta at lower levels. In contrast, cutaneous T-cell lymphoma
(CTCL) tumor tissues (seven of seven) were positive solely for GBP-5ta, and four of four CTCL cell lines expressed
both proteins. Eight of nine melanoma cell lines expressed GBP-5a/b and four of nine additionally low levels of
GBP-5ta. SEREX retesting using CTCL sera indicated a higher immunogenicity for GBP-5ta (nine of 16) than for
GBP-5a/b (two of 11). Treatment of CTCL cell lines with interferon-c did not alter protein expression of GBP-5ta
or GBP-5a/b. The restricted expression pattern of both GBP-5ta and GBP-5a/b and the pivotal role of many known
members of the GTP-binding proteins in proliferation and differentiation suggest possible cancer-related functions
of gbp-5.
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Cutaneous T-cell lymphomas (CTCL) comprise a number of
neoplasms with primary manifestation in the skin that
originate from T lymphocytes. The most common forms of
CTCL are mycosis fungoides (MF) and the Se´zary syndrome
(SS). Both are monoclonal memory T helper lymphomas.
MF is characterized by cutaneous patches, plaques, and
tumors, SS by erythroderma, lymphadenopathy, and Se´zary
cells (neoplastic T cells) in the peripheral blood (Burg et al,
1997; Willemze et al, 1997).
There are a number of standard treatment options for
CTCL including some new therapeutic drugs, but all of them
are still palliative (Dummer et al, 1996; Dippel et al, 2003).
Specific immunotherapy like vaccination with peptides or
peptide- or tumor-lysate loaded dendritic cells (Rosenberg,
1999; Maier et al, 2003) provides a promising approach
for CTCL (Duvic and Cather, 2000). Prerequisite for such
strategies is the identification of tumor-specific antigens
(Rosenberg, 1999; Rosenberg, 2001). Unfortunately, only
very few antigens have been described for CTCL (Eichmu¨l-
ler, 2002).
A new large-scale screening using a newly generated
CTCL-derived library and sera of patients suffering from
CTCL revealed a new tumor-specific antigen, guanylate-
binding protein (GBP)-5ta, which belongs to the family of
GBP proteins (Hartmann et al, 2004). The GBP are large
GTPases (  70 kDa) being able to bind GTP, GDP, and
GMP and to catalyze the hydrolysis of GTP to GDP, as well
as GMP (Cheng et al, 1985; Cheng et al, 1991; Schwemmle
and Staeheli, 1994). GTPases play an important role in cell
proliferation, differentiation, signal transduction, and intra-
cellular protein transportation (Bourne et al, 1991; Boehm
et al, 1998). Some members of GTP-binding proteins,
including the Ras-family, Rab proteins and Mx proteins,
however, do not hydrolyze GTP to GMP. Mutations in ras
genes were found in different tumors, suggesting their
involvement in the development of specific neoplasms.
These mutations result in the loss of GTPase activity and
lead to the formation of constitutively active and potentially
oncogenic proteins that could cause a deregulation of cell
cycle (Weber et al, 2000; Macaluso et al, 2002; Smythe,
2002).
Most known GBP express a CaaX isoprenylation motif at
their C-terminus (Nantais et al, 1996) and are interferon-g
(IFN-g) inducible (Patrone et al, 2002). To date, three human
GBP have been published and all mapped to chromosome
1, namely, GBP-1, GBP-2, and GBP-3 (Strehlow et al, 1994;
Neun et al, 1996; Luan et al, 2002), but the analysis of their
biological functions has only recently been started. Ander-
son et al (1999) showed that GBP-1 mediates an antiviral
effect against vesicular stomatitis virus and encephalomyo-
carditis virus. Also, GBP-1 counteracts the proliferative
effect of inflammatory cytokines like IFN-g, interleukin 1-b
(IL-1b), and tumor necrosis factor-a (TNF-a) on endothelial1These authors have contributed equally.
Abbreviations: CTCL, cutaneous T-cell lymphoma; GBP, guanylate
binding protein; IFN, interferon; MF, mycosis fungoides; SS, Se´zary
syndrome
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cells (Guenzi et al, 2001). gbp-4 (acc. no. AF288814) and
gbp-5 (acc. no. AF288815) are unpublished sequences,
which have been submitted to GenBank as open reading
frames.
Here we report the identification of three splicing variants
of the gbp-5 gene in CTCL biopsies and CTCL-derived cell
lines, which translate into two different proteins, GBP-5a/b
and GBP-5ta. Furthermore, we characterize the sero-
reactivity against these proteins, as well as RNA and
protein expression within different tissues.
Results
Screening Approximately 7  106 recombinant clones of a
cDNA library derived from CTCL tissue, cutaneous B-cell
lymphoma (CBCL) tissue as well as four CTCL cell lines
were screened by sera from patients suffering from CTCL
including MF and SS leading to nine reactive antigens
(Hartmann et al, 2004). One clone (HD-CL-05) showed high
homology to the family of guanylate-binding proteins (GBP)
and was therefore named gbp-5ta (gbp-5 tumor antigen;
accession no AF328727). gbp-5ta codes for a 490aa protein
and contains a guanylate binding site comprised of three
motifs, comparable with other GBP members. Although
GBP-1 (accession no. M55542; Strehlow et al, 1994) and
GBP-2 (accession no. M55543; Cheng et al, 1991) showed
only 80% and 77% similarity, respectively, a recently sub-
mitted ORF sequence, GBP-5 (accession no. AR035948,
unpublished), was identical in the overlapping region.
In order to identify more homologous genes we perfor-
med a cDNA-library screening of 3  105 plaques using
digoxigenin-labeled PCR products derived from primer set I
(Fig 1) as probes and the same CTCL phage library
mentioned above. Four clones could be identified: one
harbored GBP-2 in reverse orientation, the second was
identical to gbp-5ta, and two clones represented gbp-5
splicing variants, gbp-5a and -5b. gbp-5a and -5b pos-
sessed in comparison with gbp-5ta two additional exons at
the 30 end. gbp-5a lacked the second exon. The deduced
proteins of gbp-5a and gbp-5b were identical and are
therefore named GBP-5a/b (Fig 1).
gbp-5 was found on chromosome 1p22.3 (accession no.
AC021689; Fig 1) and consists of 12 exons, of which the
second is specific for gbp-5ta and gbp-5b. gbp-5ta lacks
exons 11 and 12. To confirm the existence of the shorter
gbp-5ta without exons 11 and 12 we performed a 30 RACE-
PCR using a CTCL RACE-cDNA unraveling two bands.
Cloning and sequencing of these bands revealed gbp-5ta
for the shorter and gbp-5a/-5b for the longer clone. This
indicated that gbp-5ta might be an alternative splicing
variant at the 30-end of gbp-5.
Homology Blast searches of GenBank and EMBL data-
bases revealed homologous sequences with 67% (591aa),
64% (591aa), and 68% (581aa) homology of GBP-5a/b to
the human GBP-1, GBP-2, and GBP-3, respectively.
Although gbp-5a and gbp-5b code exactly the same protein
(586aa, 67 kDa), GBP-5ta (489aa, 60 kDa) was C-terminal
truncated by 97aa.
Serological analysis Additional sera of patients diagnosed
with MF (n¼12) or SS (SS) (n¼4) and 14 control sera from
healthy volunteers were tested using gbp-5a, gbp-5b, and
gbp-5ta phage clones in a SEREX approach. Reactivity of
CTCL patients’ sera tested by SEREX resulted in nine of 16
(56%) positive sera for GBP-5ta and two per 11 (18%) for
GBP-5a/b, which has been tested using the GBP-5a coding
phage. All tested sera of healthy donors (n¼ 14) were
negative.
Expression spectrum of GBP-5 RNAs Two different
primer sets were used to analyze mRNA expression, which
could distinguish gbp-5ta/-5b and gbp-5a (Fig 1). We found
gbp-5ta/-5b in 29% and gbp-5a in 33% control tissues (bone
marrow, stomach, placenta, uterus, small intestine, spleen,
peripheral blood monocytes; Primer set I was negative for
uterus; small band in primer set II PCR was negative in
stomach; Table I). Among the investigated tumor tissues,
CTCL and CBCL were positive in 32% (primer set I) and
67% (primer set II). We found two (primer set I) and four
(primer set II) positive CTCL cell lines, only one positive
leukemia cell line (n¼5) and six (primer set I) and eight
(primer set II) positive melanoma cell lines (Table I).
Unexpectedly, the results of primer set I did not always fit
forward primer reverse primer coding sequence
primer set I
gbp-5b
gbp-5a
gbp-5ta
Chromosome
1p22.3
1 2 3 4 5 6 7 8 9 10 11 12
primer set II
Figure 1
Chromosomal alignment of gbp-5ta, gbp-5a,
and gbp-5b with chromosome 1. The scheme
depicts the chromosomal localization of all
three splicing variants and the used primers.
All identified variants were 100% homologous
to chromosome 1p22.3. Primer set I is specific
for gbp-5ta and gbp-5b, whereas primer set II
recognized all three variants leading to RT-PCR
products with two different sizes.
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to the large band of primer set II. Thus, we suppose the
existence of yet other splicing variants of gbp-5.
Expression spectrum of the GBP-5a/b and GBP-5ta
protein We generated polyclonal antibodies K25 and K26
against recombinant GBP-5ta. Antibody K25 detected a 60
kDa protein representing GBP-5ta (Fig 2A, lane 1). Antibody
K26 visualized a band of 60 kDa reflecting GBP-5ta and a
band of 72 kDa for GBP-5a/b (Fig 2B).
Western blot analysis using antibodies K25 and K26 was
performed using total protein from four CTCL cell lines and
control tissues tested positive in RT-PCR (primer set I or
primer set II; Table II). The western blot results illustrated
that all tested control tissues besides peripheral blood
monocytes (PBMC) were not reactive using either antibody.
PBMC were positive for GBP-5a/b and a faint band was
visible at the size of GBP-5ta. To specify GBP-5ta and GBP-
5a/b expression in PBMC, CD4þ and CD8þ cells were
separated from the remaining PBMC by magnetic beads
and analyzed using K26 (Fig 3). GBP-5ta was only
moderately expressed in CD4þ and CD8þ cells, whereas
GBP-5a/b was expressed in all cell types.
All four CTCL cell lines that were positive in RT-PCR
showed one band in the appropriate size of GBP-5ta with
antibody K25 (Fig 2A). Lysates of the same CTCL cell lines
incubated with antibody K26 revealed two bands indicating
the presence of both GBP-5ta and GBP-5a/b (Fig 2B). GBP-
5ta protein was detected in seven of seven CTCL patients
by western blot using antibody K26. Results are shown for
four patients (Fig 4). Tumor tissues of three patients with MF
and one with SS showed strong expression of GBP-5ta
protein and no expression of GBP-5a/b. The corresponding
lymph node of the SS patient showed a lower expression of
GBP-5ta than the tumor tissue (Fig 4, SS and SS LN). GBP-
5a/b expression was found in total protein of eight of nine
melanoma cell lines (negative: SK-Mel023), whereas a weak
band for GBP-5ta could be detected in four of nine (e.g.,
see Fig 5). The observed expression of GBP-5ta in CTCL
and melanoma cell lines could be confirmed by antibody
K25 in all cases (not shown).
Interferon-c induction assay Due to its homology to the
IFN-g inducible family of GBP we investigated the IFN-g
inducibility of GBP-5 proteins. Three CTCL cell lines (HH,
HuT-78, and MyLa) were exposed to 10 and 100 U per mL
IFN-g for 12 h. ICAM-1 was induced in HH, whereas HuT-78
and MyLa were invariable. HLA class I was weakly
upregulated only in HuT-78 (Fig 6B). The melanoma cell
line SK-Mel023 was used as positive control. ICAM-1 and
HLA class I could be induced in this cell line by treatment
with IFN-g, but GBP-5ta or GBP-5a/b were negative before
and after IFN-g induction. All tested CTCL cell lines were
positive for both proteins which remained unchanged by
IFN-g treatment, as is shown in Fig 6A.
Discussion
gbp-5 represents a new gene of the GBP-family, whose
three splicing variants are transcribed into two different
proteins (GBP-5a/b and GBP-5ta). GBP-5ta is a 97aa-
Table I. RT-PCR analyses using antigen-speciﬁc primers and cDNA from various kinds of control tissues, tumor tissues,
and tumor cell lines
Primer set I Primer set II
gbp-5ta/gbp-5b gbp-5ta/gbp-5b gbp-5a
Normal tissues (n¼ tissues) (%) adult tissues (n¼21) 29 33 29
fetal tissues (n¼8) 0 50 50
Tumor tissue (n¼donors) (%) CTCL (n¼19) 32 58 37
CBCL (n¼3) 67 67 67
Cell lines (n¼donors) (%) Melanoma (n¼ 19) 42 42 32
CTCL (n¼ 4) 100 50 50
Leukemia (n¼5) 20 20 0
The table summarizes the percentage of positive normal tissues (each tissue pooled from several donors) and of positive tumor tissues and cell lines
when analyzed by RT-PCR using primer sets I and II. Primer set I resulted in a single band, whereas primer set II amplified a large band specific for
gbp-5ta/gbp-5b and a small band for gbp-5a (see Fig 1).
A
60 kDa
β-actin
51 2 3 4 6 7 8 9
B
72 kDa
60 kDa
51 2 3 4 6 7 8
β-actin
K26
K25
Figure 2
GBP-5ta and GBP-5a/b protein expression in CTCL cell lines and
control tissues. A: Antibody K25 detected GBP-5ta, only, which was
labeled as a band of 60 kDa in the four CTCL cell lines but not in any of
the control tissues. Recombinant GBP-5ta (lane 1), CTCL cell lines (2:
MyLa, 3: HuT-78, 4: HH, 5: SeAx), and control tissues (6: testis, 7: fetal
liver, 8: uterus, 9: placenta). B: Antibody K26 labeled GBP-5ta and
GBP-5a/b as bands of 60 and 72 kDa, respectively, in the four CTCL
cell lines (1: MyLa, 2: HuT-78, 3: SeAx, 4: HH). All control tissues (5:
bone marrow, 6: testis, 7: stomach) besides PBMC (lane 8) were
negative.
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truncated variant of GBP-5a/b. More than 50% of CTCL
sera, but none of the control sera reacted with GBP-5ta
protein, suggesting a strong immunogenicity of this tumor
antigen. Interestingly, the truncated GBP-5 protein, GBP-
5ta, revealed a stronger antibody response than the full-
length protein GBP-5a/b.
gbp-5ta mRNA was found to be expressed in selected
normal tissues. RT-PCR detected gbp-5ta/-5b in 26%–58%
of CTCL tumor tissues and in 45% of melanomas. By
means of two newly generated antibodies we were able to
investigate the expression of the two proteins by Western
blot. All control tissues tested were negative for both GBP-
5a/b and GBP-5ta, with the exception of PBMC, which were
positive for GBP-5a/b and weakly positive for GBP-5ta. A
detailed analysis of PBMC subpopulations indicated that
GBP-5ta was expressed in CD4þ and CD8þ as a faint
band only, whereas GBP-5a/b was expressed in all PBMC
cell types analyzed. In CTCL-tumor samples only GBP-5ta
was detectable, and eight of nine melanoma cell lines
expressed GBP-5a/b and four of nine GBP-5ta protein. In
contrast, CTCL cell lines were positive for both GBP-5a/b
and GBP-5ta. The observed discrepancy between mRNA
Table II. Comparative analysis of mRNA and protein expression
RT-PCR
Western blot
GBP-5ta/GBP-5a/b
Primer set I Primer set II
gbp-5ta/-5b gbp-5ta/gbp-5b gbp-5a
CTCL cell lines HH þ þ þ þ
HuT-78 þ þ þ þ
MyLa þ þ þ þ
SeAx þ þ þ þ
Bone marrow þ þ þ 
Brain    
Colon    
Fetal liver    
Mammary gland    
PBMCs þ þ þ þ
Placenta þ þ þ 
Control tissues Prostate    
Skeletal muscle    
Small intestine þ þ þ 
Spleen þ þ þ 
Stomach þ þ  
Testis    
Trachea    
Uterus  þ þ 
The table compares the expression of mRNA as analyzed by RT-PCR and protein as analyzed by Western blotting in control tissues and CTCL cell
lines (HH, HuT-78, MyLa, SeAx). RT-PCR positive control tissues were tested negative in the Western blot except PBMCs, while GBP-5ta and GBP-5a/b
protein could be detected in all CTCL cell lines. The following normal tissues were tested negative in all RT-RCR experiments and therefore not included
in Western blot analysis: Heart, kidney, liver, lung, ovary, skin, thymus, and 8 fetal tissues (brain, heart, kidney, liver, lung, skeletal muscle, spleen, and
thymus).
K26
3 41 2
β-actin
60 kDa
72 kDa
Figure 3
Expression analysis of GBP-5ta and GBP-5a/b in PBMC. Antibody
K26 detected GBP-5a/b in CD4þ (lane 2), CD8þ (lane 3) and in the
remaining cells (lane 4) whereas GBP-5ta is only weakly expressed in
CD4þ and CD8þ cells and not in the remaining cells. Lane 1: total
PBMC.
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detection and protein expression has also been reported for
other genes: mRNA of the tumor antigens SART-1 and
SART-3 have been detected in normal tissue by Northern
blot, and the protein was only found in tumor tissues
(Shichijo et al, 1998; Kikuchi et al, 1999).
IFN-g treatment has been shown to induce the expres-
sion of guanylate-binding proteins in both murine and
human cells (Strehlow et al, 1994; Nantais et al, 1996;
Stickney and Buss, 2000; Gorbacheva et al, 2002). There-
fore, we have investigated the IFN-g inducibility of GBP-5.
The Western blot suggested an unresponsiveness of both
GBP-5ta and GBP-5a/b to IFN-g as the protein level was
not altered which might be explained by IFN-g resistance of
CTCL derived tumor cells. IFN-g resistance is suggested to
be a pathway for Th2 tumor cells to avoid inhibition by
reactive Th1 lymphocytes (Dummer et al, 2001). Addition-
ally, ICAM-1 and HLA class I were induced only in one of
three CTCL cell lines, each. Normally HLA class I molecules
and ICAM-1 were found to be upregulated by IFNs (Garbe
and Krasagakis, 1993). A melanoma cell line known to be
inducible by IFN- (SK-Mel023) was also tested for GBP-5ta
and -5a/b expression. We did not detect any GBP-5ta or
GBP-5a/b irrespectively whether the cell line was treated by
IFN-g or not.
A well-known member of the GTPases is the Ras protein
with its oncogenic mutant variants. Five domains are
essential for Ras activity (Macaluso et al, 2002). Mutations
in these regions block the hydrolysis of GTP, leading to the
expression of constitutively active protein, which stimulates
the cells to uncontrolled proliferation (Scheffzek et al, 1998;
Ahmadian et al, 1999). Cystein mutation in the CaaX box
prevents farnesylation and Ras function (Hancock et al,
1989; Schafer et al, 1989).
Sequence comparisons suggest that GBP-5a/b may
have GTPase and isoprenylation properties similar to those
of GBP-1, the best studied GBP family member (Prakash
et al, 2000). The CaaX box of GBP-5a/b consists of cystein–
valin–leucin–leucin. Post-translational modifications of the
CaaX box increase the hydrophobicity by isoprenylation of
the cystein, leading to integration into the plasma mem-
brane (Clarke, 1992; Casey, 1995). GBP-5ta lacks 97aa of
its C-terminus including the CaaX box, which might result in
an inability of membrane integration of GBP-5ta, whereas
GBP-5a/b can be isoprenylated.
Murine GBP-5, which is similar to human GBP-5, has
been found in two splicing variants (Nguyen et al, 2002).
MuGBP-5 contains two GTP-binding motifs and one
isoprenylation site at the C-terminus. MuGBP-5a is N-
terminally truncated by 112aa and C-terminally extended,
but lacks the isoprenylation motif. Thus, both human and
murine GBP-5 appear in different splicing variants of which
one has lost its isoprenylation site.
GBP-1 was found to have an anti-proliferative activity on
endothelial cells independent of its GTPase function and the
isoprenylation motif. Guenzi et al (2001) cloned cDNA
fragments encoding either the N-terminal or the C-terminal
domains to identify the functional component. They
demonstrated that the N-terminal domain has nearly no
inhibitory effect, whereas the C-terminus is sufficient to
inhibit endothelial cell proliferation. Notably, GBP-5ta also
has lost its C-terminus, which may have an important
MF 1 MF 2 SS SS LN MF 3
60 kDa
β-actin
K26
Figure 4
GBP-5ta protein was detected in CTCL tumor tissues. Representa-
tive western blot with protein lysates from CTCL tumor tissue of four
different patients (3 MF and 1 SS; patient MF1 suffered additionally
from Hodgkin lymphoma) and from a corresponding lymph node (SS
LN). Antibody K26 labeled a singular band (60 kDa), only, representing
GBP-5ta.
72 kDa
60 kDa
51 2 3 4 6
β-actin
K26
Figure 5
Melanoma cell lines express mainly GBP-5a/b. Six melanoma cell
lines stained with K26. GBP-5a/b was visible as a band of 72 kDa in six
of six tested melanoma cell lines. GBP-5ta was expressed weakly in
four of six (lanes 2, 4, 5, 6). 1: Ma-Mel-17, 2: Ma-Mel-37a, 3: Ma-Mel-
05, 4: Ma-Mel-42a, 5: Ma-Mel-04, 6: Ma-Mel-12.
β-actin
HLA class I
80 kDa
38 kDa
128 kDa
80 kDa ICAM-1
0 10 100
HuT-78 MyLa
0 10 100IFN- γ [U/ml] 0 10 100
HH
60 kDa
72 kDa
IFN- γ [U/ml] 0 10 100
HuT-78 MyLa
0 10 100
β-actin
A
B
K26
Figure6
IFN-c did not alter GBP-5 protein expressions. The CTCL cell lines
HuT-78 and MyLa were induced with 0, 10, and 100 U per mL IFN-g for
12h. A: Antibody K26 detected GBP-5ta as a band of 60 kDa and GBP-
5a/b as a band of 72 kDa in both CTCL cell lines, irrespective of the
IFN-g treatment. B: IFN-g induced ICAM-1 in HH (arrow) and HLA class
I in HuT-78 (arrow), only.
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impact on the potential proliferation inhibitory function of
GBP-5ta.
GBP-5ta and GBP-5a/b might be promising targets for
therapy: Both proteins are expressed in CTCL tumor cells,
melanoma cells and in PBMC, but in no other control
tissues and the expression level of GBP-5ta is higher in
CTCL than in normal PBMC. GBP-5ta and GBP-5a/b are
recognized by the immune system of many CTCL-patients,
but not of healthy volunteers. Most interestingly, gbp-5
derived proteins belong to a well-known family of GTPases
involved in cancerogenesis. Ongoing analyses will prove
whether these new proteins have similar functions in CTCL
and possibly other malignancies.
Material and Methods
Tissue, sera, and cell lines All human specimens were obtained
after informed consent and approval of the local ethical committee.
Sera and tumor tissues were acquired during routine diagnostic or
therapeutical procedures and were stored at 201C and 801C,
respectively. Tissue specimens obtained from 19 CTCL and three
CBCL (cutaneous B cell lymphoma) patients served as source for
generation of tumor cDNA. The CTCL comprised: 14 MF (stage Ib
to IVb, mainly IIb), three SS (stage III), one T-zone lymphoma (stage
IVb), and one CD30þCTCL (stage IIb). Additionally, cDNA from the
following four CTCL cell lines was generated: MyLa (MF; Kaltoft et
al, 1992), SeAx (SS; Kaltoft et al, 1988), HH (SS, ATCC number:
CRL-2105), and HuT-78 (SS, ATCC Number: TIB-161). Further-
more, we generated cDNA from six leukemia cell lines (ARA-10,
Jurkat, KG1, K562, Nalm-2, and SKW6.4) and from 19 melanoma
cell lines. A variety of control cDNAs were used for analyzing tissue
distribution within normal tissues, including three panels of
commercially available cDNAs (all Clontech, California).
Screening and evaluation of sero-reactivity GBP-5ta was
identified by a SEREX screening using a cutaneous lymphoma
tumor library, generated from mRNA of the CTCL cell lines HuT-78,
HH, MyLa and SeAx, CTCL tumor tissues (MF and SS) and tumor
tissue of a patient suffering from CBCL (Hartmann et al, 2004). The
SEREX screening and retesting were performed as described
previously. Briefly, pre-absorbed sera from up to 16 CTCL patients
and 14 healthy donors were used to determine the immunogenicity
of the phage clones in at least two independent SEREX
experiments. To identify GBP-5ta homologous genes, a cDNA
library screening (HYREX) similar to the SEREX approach was
performed as described previously (Usener et al, 2003).
Sequence analysis Sequencing was done at the central facilities
of the German Cancer Research Center. Computational analysis
was done using the HUSAR package from the Biocomputing
Service Group at the German Cancer Research Center. All
sequences were analyzed with prime, map and 2dsweep. Data-
base searches were performed on EMBL and GenBank databases
with blast programs for nucleic acids and amino acids.
RT-PCR Due to limited amounts of RNA, RT-PCR was preferably
used for investigating expression patterns of identified sequences
within different normal and tumor tissues. RNA was isolated using
QIA shredder mini columns and RNeasy mini kit (both Qiagen,
Hilden, Germany). The location of primers is given in Fig 1. The
primer sequences were (length of PCR-product and annealing
temperatures are given in brackets): gbp-5ta, primer set I for: 50-
cgg aca cgc taa ttg ttg tag-30 and rev: 50-cca tat cca aat tcc ctt ggt
gtg ag-30 (364 bp; 631C); gbp-5ta/b and gbp-5a, primer set II for:
50-aga agg aag aaa ctc caa aca cat cc-3 and rev: 50-cca tat cca aat
tcc ctt ggt gtg ag –30(gbp-5ta/b: 515 bp, gbp-5a: 408 bp; 481C). A
standard protocol was used for RT-PCR (951 per 1 min, annealing
per 1 min, 721 per 2 min, 35 cycles) using a MJ Research PCT-200
(Biozyme, Oldendorf, Germany) according to Eichmu¨ller et al
(2001).
Rapid ampliﬁcation of cDNA ends (RACE) 30 RACE-PCR was
performed using a primer located within gbp-5ta (1557 cca gga gct
gct gga cct gca cag gac 1583) to verify the different 30 splicing
variants. Smart II Oligo labeled 30 cDNA (Smart cDNA amplification
kit; BD Clontech, Heidelberg, Germany) was synthesized using the
lymphoma library RNA. The proof reading Advantage2 PCR
polymerase mix (Clontech) was used according to the manufac-
turer’s protocol. The amplificons were cloned into the pCR TOPO4
vector (Invitrogen, Groningen, Netherlands) and sequenced.
Antibodies His-tagged GBP-5ta fusion protein was affinity pur-
ified on Ni2þ -agarose columns (Invitrogen) and separated by a
SDS-PAGE. The recombinant GBP-5ta protein was cut out of the
gel and the first 13 amino acids at the N-terminal have been
sequenced to prove the identity of the protein. The denatured
protein was used for generation of two polyclonal rabbit antibodies
K25 and K26 (four immunizations on day 1, 7, 14, 28; customized
service of BioGenes, Berlin, Germany; following the companies
standard protocol). Mouse Anti-actin was purchased from Diano-
va, Hamburg, Germany.
Antibodies K25 and K26 were tested for specificity in a GST
capture ELISA as described by Sehr et al (2001). Recombinantly
expressed GBP-5ta protein was used as positive control and
another antigen, se70-2, was used as negative control. The
antibodies were diluted from 1:50 to 1:10,000. At a concentration
of at least 1:1000 both antibodies specifically detected recombi-
nant GBP-5ta (Fig 7).
Western blot Western blot was performed using 20 mg protein
from total cell lysate and commercial protein medleys of normal
tissues (Clontech, Palo Alto, California, USA or BioChain, Hayward,
California, USA). Cell pellets of four CTCL cell lines and nine
melanoma cell lines (Ma-Mel-04, Ma-Mel-05, Ma-Mel-12, Ma-Mel-
17, Ma-Mel-36, Ma-Mel-37a, Ma-Mel-42a, SK-Mel023, and UKRV-
Mel-10) were used. Protein was isolated using Triton-X100 and
Tris–HCl, separated on SDS-PAGE and blotted onto nitrocellulose
membranes (Satorius, Go¨ttingen, Germany). Blots were incubated
with a 1:1000 dilution of K25 and K26 antibodies for 1 h at room
temperature. Secondary HRP-coupled anti-rabbit antibody (Dia-
nova, Hamburg, Germany) was used at a dilution of 1:10,000. The
0
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Figure7
Specificity tests of the antibodies K25 and K26 by ELISA. The ELISA
was done using recombinant GST-fusion protein GBP-5ta and the
unrelated se70-2 and different dilutions of the antibodies K25 and K26.
Both antibodies were specific for recombinantly expressed GBP-5ta at
a dilution of 1:1000.
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antibody binding was visualized by ECL-staining (Amersham
Bioscience, Buckinghamshire, UK). The specificity of the anti-
bodies was tested by using pre-immune serum of the same animal
under the same conditions. All these control western blots were
negative. As control for equal amounts of protein a second western
blot was done using the same protein lysates and a mouse anti-b-
actin antibody (Dianova, Hamburg, Germany).
Magnetic cell sorting and separation of CD4þ and CD8þ
cells CD4þ and CD8þ cells were isolated from PBMC by
magnetic cell sorting (Miltonyi Biotech GmbH, Bergisch Gladbach,
Germany) as described by the manufacturer. Twenty mg protein
extract of the cell pellets were analyzed by western blot.
Interferon- induction assay CTCL cell lines (HuT-78, HH, MyLa)
were treated with 0, 10, and 100 U per mL human IFN-g (RD
Systems, Wiesbaden, Germany) for 12 h. Protein was extracted
(PeqGold TriFast, Peqlab, Erlangen, Germany) and analyzed by
western blot using antibody K25 and K26. The melanoma cell line
SK-Mel023 was used as positive control for the successful
induction of ICAM-1 and HLA class I by treatment with IFN-g.
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